Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -59.31% is 19% above its 5-year average of -72.92%, near the high end of its 5-year range (-114.15%–-49.18%).
5.98% above its 12-month average of -63.08%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -81.53%.
EBITDA MARGIN
-59.31%
EBITDA MARGIN AVG TTM
-63.08%
EBITDA MARGIN AVG 3Y
-62.65%
EBITDA MARGIN AVG 5Y
-72.92%
EBITDA MARGIN AVG 10Y
-68.94%
EBITDA MARGIN AVG 15Y
-80.65%
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+5.98%
CURRENT VS 3Y AVG
+5.34%
CURRENT VS 5Y AVG
+18.66%
CURRENT VS 10Y AVG
+13.97%
CURRENT VS 15Y AVG
+26.46%
CURRENT VS 20Y AVG
N/A
ClearPoint Neuro, Inc.
Market Cap
$345.48M
EBITDA Margin
-59.31%
TTM Avg
-63.08%
3Y Avg
-62.65%
5Y Avg
-72.92%
Market Cap
$348.59M
EBITDA Margin
-25837.05%
TTM Avg
-12960.93%
3Y Avg
-7440.06%
5Y Avg
-7440.06%
Market Cap
$330.60M
EBITDA Margin
-285.23%
TTM Avg
-308.13%
3Y Avg
-415.00%
5Y Avg
-335.56%
Market Cap
$361.64M
EBITDA Margin
-271.53%
TTM Avg
-418.08%
3Y Avg
-211.46%
5Y Avg
-940.00%
Market Cap
$329.01M
EBITDA Margin
-184.07%
TTM Avg
-174.53%
3Y Avg
-153.81%
5Y Avg
-153.81%
Market Cap
$366.39M
EBITDA Margin
-122.86%
TTM Avg
-149.66%
3Y Avg
-152.47%
5Y Avg
-125.05%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ClearPoint Neuro, Inc. (CLPT) | $345.48M | -59.31% | -63.08% | -62.65% | -72.92% |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $348.59M | -25837.05% | -12960.93% | -7440.06% | -7440.06% |
| Embecta Corp. (EMBC)vs › | $348.85M | 35.21% | 27.25% | 28.55% | 34.67% |
| Cabaletta Bio, Inc. (CABA)vs › | $339.15M | N/A | N/A | N/A | N/A |
| C4 Therapeutics, Inc. (CCCC)vs › | $330.60M | -285.23% | -308.13% | -415.00% | -335.56% |
| Opus Genetics, Inc. (IRD)vs › | $361.64M | -271.53% | -418.08% | -211.46% | -940.00% |
| CapsoVision, Inc. (CV)vs › | $329.01M | -184.07% | -174.53% | -153.81% | -153.81% |
| Agenus Inc. (AGEN)vs › | $363.54M | -9.24% | -56.39% | -95.53% | -82.66% |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $366.39M | -122.86% | -149.66% | -152.47% | -125.05% |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $368.91M | -13.98% | -3.54% | -384.69% | -2364.58% |
Gross Margin
62.6%
EBITDA Margin
-59.3%
Operating Margin
-65.4%
Net Margin
-81.8%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -81.53% |
| 2026-03-31 | -60.73% |
| 2025-12-31 | -59.50% |
| 2025-09-30 | -58.80% |
| 2025-06-30 | -54.85% |
| 2025-03-31 | -68.70% |
| 2024-12-31 | -66.05% |
| 2024-09-30 | -57.58% |
| 2024-06-30 | -54.42% |
| 2024-03-31 | -49.18% |
| 2023-12-31 | -62.88% |
| 2023-09-30 | -77.65% |
| 2023-06-30 | -114.15% |
| 2023-03-31 | -100.15% |
| 2022-12-31 | -83.42% |
| 2022-09-30 | -70.44% |
| 2022-06-30 | -76.33% |
| 2022-03-31 | -72.45% |
| 2021-12-31 | -88.81% |
| 2021-09-30 | -79.14% |
| 2021-06-30 | -94.52% |
| 2021-03-31 | -50.45% |
| 2020-12-31 | -52.74% |
| 2020-09-30 | -33.90% |
| 2020-06-30 | -56.17% |
| 2020-03-31 | -36.14% |
| 2019-12-31 | -42.03% |
| 2019-09-30 | -29.01% |
| 2019-06-30 | -47.29% |
| 2019-03-31 | -36.88% |
| 2018-12-31 | -41.77% |
| 2018-09-30 | -65.32% |
| 2018-06-30 | -97.92% |
| 2018-03-31 | -85.96% |
| 2017-12-31 | -107.72% |
| 2017-09-30 | -75.74% |
| 2017-06-30 | -90.72% |
| 2017-03-31 | -65.64% |
| 2016-12-31 | -107.62% |
| 2016-09-30 | -103.51% |
| 2016-06-30 | -181.85% |
| 2016-03-31 | -135.77% |
| 2015-12-31 | -90.06% |
| 2015-09-30 | -153.30% |
| 2015-06-30 | -318.73% |
| 2015-03-31 | -282.87% |
| 2014-12-31 | -270.47% |
| 2014-09-30 | -399.52% |
| 2014-06-30 | -176.81% |
| 2014-03-31 | 277.76% |
| 2013-12-31 | -169.00% |
| 2013-09-30 | -188.30% |
| 2013-06-30 | -366.50% |
| 2013-03-31 | -99.07% |
| 2012-09-30 | -81.36% |
| 2012-06-30 | 156.14% |
| 2012-03-31 | -107.43% |
| 2011-09-30 | -80.17% |
| 2011-06-30 | -203.40% |
